Kidney Regeneration

Current Situation

Acute kidney injury (AKI) is defined as an abrupt or rapid decline in renal filtration function. The stage of AKI is based on increased serum creatinine and urea levels concurrent with decreased urine output. Many chemotherapeutic agents, such as Cisplatin, are known to induce renal cell death. Even though the nephrotoxicity of cisplatin has been recognized since its introduction over 30 years ago, it is still widely used in the treatment of many solid-organ cancers, including those of the head, neck, lung, testis, ovary, and breast due to its highly effective anti-cancerogenic effect. 



The majority of research on the therapeutic advantages of mesenchymal stem cells (MSCs) has already proven effective in reducing AKI in experimental models. Pre-trials regarding the differentiation potential of ABCB5+ cells show that these can differentiate into functioning renal endothelial cells. Thus, stem cell ther­apy with ABCB5+ MSCs represents a promising approach to renal cell regeneration.



The precise effect in vivo and in vitro is currently studied in further tri­als.




« zurück

Clinical Trials

We are now also recruiting patients for further clinical studies in phase I/IIa with allogeneic ABCB5-positive (ABCB5+) mesenchymal stem cells for the following indications: chronic venous ulcers (CVU), diabetic foot ulcers (DFU) and peripheral arterial occlusive disease (PAOD). For more information click HERE.


Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.